November/December 2011

The Generic Wave Arrives

December 12, 2011

The American Journal of Pharmacy Benefits

When a new generic comes to market, we need to think not only about the financial implications but also about the message conveyed to patients.

Cost-Effectiveness of Fingolimod in Treating Patients With Relapsing-Remitting Multiple Sclerosis

December 12, 2011

The American Journal of Pharmacy Benefits

Fingolimod, a first-line, once-daily oral disease-modifying therapy for relapsing-remitting multiple sclerosis, has the lowest cost per relapse avoided compared with other first-line agents.

Developing a Global Strategy to Combat Noncommunicable Diseases

December 09, 2011

The American Journal of Pharmacy Benefits

WHO'S commitment to addressing the impact of 4 common noncommunicable diseases will ultimately lead to improvements for patients with a broad range of chronic conditions.